Compare Glenmark Pharma with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs VENUS REMEDIES - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA VENUS REMEDIES GLENMARK PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 11.6 -1.2 - View Chart
P/BV x 1.5 0.1 1,831.0% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 GLENMARK PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
VENUS REMEDIES
Mar-18
GLENMARK PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs712126 565.2%   
Low Rs48461 791.5%   
Sales per share (Unadj.) Rs349.6301.8 115.9%  
Earnings per share (Unadj.) Rs32.8-24.9 -131.8%  
Cash flow per share (Unadj.) Rs44.32.5 1,742.2%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs198.6293.3 67.7%  
Shares outstanding (eoy) m282.1712.34 2,286.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.70.3 551.7%   
Avg P/E ratio x18.2-3.8 -484.9%  
P/CF ratio (eoy) x13.536.7 36.7%  
Price / Book Value ratio x3.00.3 943.6%  
Dividend payout %6.10-   
Avg Mkt Cap Rs m168,6251,154 14,614.9%   
No. of employees `00012.00.9 1,301.3%   
Total wages/salary Rs m20,561393 5,230.4%   
Avg. sales/employee Rs Th8,196.04,026.1 203.6%   
Avg. wages/employee Rs Th1,708.1425.0 401.9%   
Avg. net profit/employee Rs Th768.5-331.8 -231.6%   
INCOME DATA
Net Sales Rs m98,6553,724 2,649.1%  
Other income Rs m2,08123 9,250.5%   
Total revenues Rs m100,7363,747 2,688.7%   
Gross profit Rs m15,858395 4,016.8%  
Depreciation Rs m3,259338 963.4%   
Interest Rs m3,346354 944.4%   
Profit before tax Rs m11,335-275 -4,117.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,75632 11,887.3%   
Profit after tax Rs m9,250-307 -3,014.0%  
Gross profit margin %16.110.6 151.6%  
Effective tax rate %33.1-11.5 -288.7%   
Net profit margin %9.4-8.2 -113.8%  
BALANCE SHEET DATA
Current assets Rs m66,9682,638 2,538.9%   
Current liabilities Rs m40,2112,305 1,744.8%   
Net working cap to sales %27.18.9 303.3%  
Current ratio x1.71.1 145.5%  
Inventory Days Days83135 61.5%  
Debtors Days Days8146 175.3%  
Net fixed assets Rs m33,3224,871 684.1%   
Share capital Rs m282123 228.7%   
"Free" reserves Rs m55,7703,496 1,595.4%   
Net worth Rs m56,0523,619 1,548.8%   
Long term debt Rs m35,7381,374 2,600.2%   
Total assets Rs m132,8887,509 1,769.8%  
Interest coverage x4.40.2 1,967.7%   
Debt to equity ratio x0.60.4 167.9%  
Sales to assets ratio x0.70.5 149.7%   
Return on assets %9.50.6 1,501.5%  
Return on equity %16.5-8.5 -194.6%  
Return on capital %17.81.6 1,126.1%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m62,9980-   
Fx outflow Rs m22,859517 4,425.7%   
Net fx Rs m40,140-517 -7,771.5%   
CASH FLOW
From Operations Rs m13,242514 2,574.2%  
From Investments Rs m-6,990-123 5,678.2%  
From Financial Activity Rs m-7,387-387 1,908.4%  
Net Cashflow Rs m-2,9714 -70,733.3%  

Share Holding

Indian Promoters % 48.3 32.9 147.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 0.2 3,833.3%  
FIIs % 34.4 0.6 5,931.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 66.4 15.8%  
Shareholders   56,727 20,121 281.9%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   CADILA HEALTHCARE  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  DISHMAN PHARMA  FULFORD INDIA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; FMCG and Metal Stocks Gain(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 2% while the Hang Seng is down 0.3%.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

These Rebirth of India Stocks Are Raring to Compete with Tesla(The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

Corona Virus Could Trigger a Rally in this Stock(Profit Hunter)

Feb 20, 2020

A company which benefits from crude oil and coronavirus - if you would like to know more about it read this.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 25, 2020 11:45 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS